MedTrace Logo

Optimising Cardiovascular Health in Endometrial Cancer Survivors

NCT05216913 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-05-16

No results posted yet for this study

Summary

Women successfully treated for endometrial cancer remain at higher risk of dying than women without a history of the disease, predominately due to an excess risk of cardiovascular disease. Our previous work has shown that endometrial cancer survivors are more likely to have undiagnosed and undertreated cardiovascular risk factors than the general population, despite being seen regularly by medical professionals. This study aims to determine the impact of optimising modifiable cardiovascular risk factors in endometrial cancer survivors on their quality of life and to identify barriers to lifestyle modifications.

Conditions

Interventions

BEHAVIORAL

Lifestyle modification

Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake

DRUG

Cardiovascular Agents, Other

Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine

OTHER

QRISK 3 Score

Could include a combination of lifestyle measures and/or cardiovascular agents as described above

Sponsors & Collaborators

  • University of Manchester

    lead OTHER

Principal Investigators

  • Emma Crosbie · University of Manchester

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-09
Primary Completion
2024-04-30
Completion
2024-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05216913 on ClinicalTrials.gov